<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563677</url>
  </required_header>
  <id_info>
    <org_study_id>ZSE-DUO_V1</org_study_id>
    <nct_id>NCT03563677</nct_id>
  </id_info>
  <brief_title>Dual Guidance Structure for Evaluation of Patients With Unclear Diagnosis in Centers for Rare Diseases</brief_title>
  <acronym>ZSE-DUO</acronym>
  <official_title>Duale Lotsenstruktur Zur Abklärung Unklarer Diagnosen in Zentren für Seltene Erkrankungen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Aachen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allianz Chronischer Seltener Erkrankungen ACHSE e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Westfälische Wilhelms-Universität Münster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Josef Hospital Bochum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Otto-von-Guericke University Magdeburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IKK gesund plus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Techniker Krankenkasse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AOK Hessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In people suffering from a rare disease the diagnostic process and the confirmation of a
      final diagnosis is often ongoing for many years. Factors contributing to delayed diagnosis
      include the limited knowledge of health care professionals about rare diseases and their
      symptoms but also a psychiatric or psychosomatic (co-)morbidity obscuring the symptoms of the
      rare disease. The project ZSE-DUO will evaluate whether a combination of an expert in somatic
      medicine and a psychiatric/psychosomatic specialist will increase the rate of assured
      diagnoses in patients approaching a center of rare diseases (primary outcome), accelerate the
      process until a diagnosis is made, reduce the costs of diagnosing a patient, and lead to a
      higher satisfaction of patients and health care professionals. Furthermore, the project will
      evaluate whether the use of psychosomatic screening tools at registration of a patient in a
      center for rare diseases will help to guide the diagnostic process. Two cohorts of 682
      patients each will be sequentially recruited over 9 plus 9 months: the Control group cohort
      (CG based on somatic expertise) and the Experimental group cohort (EG combined
      psychosomatic/somatic expertise Included will be persons from the age of at least 12 years
      presenting with symptoms and signs which are not explained by current diagnoses (as judged by
      the patient's primary care physician and a specialized physician at the center for rare
      diseases ZSE evaluating the medical records). Patients will be recruited from 11 German
      Centers for Rare Diseases associated with University hospitals in the cities of Aachen,
      Bochum, Frankfurt, Hannover, Magdeburg, Mainz, Münster, Regensburg, Tübingen, Ulm and
      Würzburg. Recruitment will be supported by a collaboration with the German patient
      organization representing many rare disease organizations ACHSE e.V. and a collaboration with
      the insurance companies Techniker Krankenkasse, IKK gesund plus and AOK Hessen who also
      provide data on costs of care. Data collection and analysis will be coordinated and performed
      by the Institute for Clinical Epidemiology and Biometry at the University of Würzburg, the
      Institute for Epidemiology, Social Medicine and Science of Health Care Systems in Hannover,
      and the Department of Medical Psychology in Hamburg. The project is funded by the
      Innovationsfond of the Federal Joint Committee in Germany.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Recruitment of 682 patients into control group during first 12 months of the project and, thereafter, recruitment of 682 patients during subsequent 12 months</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnoses made</measure>
    <time_frame>12 months after signing the consent form</time_frame>
    <description>The number of diagnoses explaining the symptomatology of the patient made during the evaluation process</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to diagnosis</measure>
    <time_frame>12 months after signing the consent form</time_frame>
    <description>The time it takes to make a diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with diagnostic process using ZUF-8</measure>
    <time_frame>12 months after signing the consent form</time_frame>
    <description>The patients' satisfaction with the diagnostic process is assessed in the total sample with the questionnaire ZUF-8 (Fragebogen zur Patientenzufriedenheit - patient satisfaction questionnaire) and in a randomly selected subsample of about 40 patients by structured telephone interviews.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of the diagnostic process</measure>
    <time_frame>up to 12 months after signing the consent from</time_frame>
    <description>estimated costs from first contact with the center for rare diseases until a diagnosis explaining the symptoms has been established</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life using EQ-5D and SF12 (or KIDSCREEN-10 for children)</measure>
    <time_frame>12 months after signing the consent from</time_frame>
    <description>Change in the patients' quality of life as assessed with the Quality of life questionnaires EQ-5D from the EuroQoL Group in all patients and Short Form 12 (SF-12) in patients 16 years and older. In patients younger than 16 years, the health-related quality of life questionnaire for children and adolescents KIDSCREEN-10 is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician satisfaction with new form of care using new questionnaire</measure>
    <time_frame>30 months after the project start (end of the intervention period)</time_frame>
    <description>The satisfaction of physicians working in the Centers fro Rare Diseases with the new form of care compared to standard care will be assessed by a newly developed questionnaire administered to all physicians involved in patient care in the 11 centers. For the development of the questionnaire, 3 focus groups of 10 physicians each will be questioned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of screening instruments for psychiatric-psychosomatic (co-)morbidities</measure>
    <time_frame>30 months after the project start (end of intervention period)</time_frame>
    <description>Performance of screening tools to identify patients with psychiatric-psychosomatic comorbidities against the judgement of a psychiatrist/psychosomatic expert seeing the patient (intervention group only)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1364</enrollment>
  <condition>Rare Diseases</condition>
  <condition>Orphan Diseases</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard evaluation process for patients approaching a center for rare diseases with an unclear diagnosis. The process includes the evaluation of complete medical records byan experienced physician, an outpatient visit to the center, and case discussion between experts. The process may also include an inpatient stay, a local case conference and a case conference between centers for rare diseases from different cities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New Innovative Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The innovative evaluation process includes the additional involvement of a psychiatrists/psychosomatic expert in all of the processes described for the usual care arm plus the option to use telemedicine in the process of evaluation in addition to outpatient and inpatient visits and to transfer the patient back into standard care (i.e., primary care physician, rehabilitation, psychological/psychosomatic specialized care, etc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dual expert guidance structure</intervention_name>
    <description>Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together</description>
    <arm_group_label>New Innovative Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first contact with the Center for Rare Diseases for unclear diagnosis

          -  suspicion of a rare disease but no established diagnosis

          -  attending the Center for Rare Diseases as an outpatient

          -  written informed consent

        Exclusion Criteria:

          -  age &lt;12 years

          -  incomplete medical records including summary letters, imaging studies, blood tests
             etc.

          -  pre-diagnosed disease(s) explaining all symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Helge Hebestreit, MD</last_name>
    <phone>+49 931 201 27889</phone>
    <email>hebestreit@uni-wuerzburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefanie Draxler</last_name>
    <phone>+49 931 201 27729</phone>
    <email>draxler_s@ukw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Rare Diseases ZESE, University Hospital</name>
      <address>
        <city>Würzburg</city>
        <state>Bavaria</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helge Hebestreit, MD</last_name>
      <phone>+49 931 201 27889</phone>
      <email>hebestreit@uni-wuerzburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefanie Draxler</last_name>
      <phone>+49931 201 27729</phone>
      <email>draxler_s@ukw.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Center for Rare Diseases ZSEA, University Hospital</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Schippers, Dr.</last_name>
      <phone>+49 241 80 85651</phone>
      <email>ZSEA@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Rare Diseases CeSER, St. Josef Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Morzuch</last_name>
      <phone>+ 49 234 509 2601</phone>
      <email>info@ceser.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Rare Diseases FRZSE, UNiversity Hospital</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas OF Wagner, Prof. Dr.</last_name>
      <phone>+49 69 6301 84318</phone>
      <email>FRZSE@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Rare Diseases, Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Zeidler</last_name>
      <phone>+49 511 557105</phone>
      <email>Zeidler.Cornelia@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Rare Diseases MKSE, Otto von Guericke University</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Mohnike, Prof. Dr.</last_name>
      <phone>+49 345 1325 9595</phone>
      <email>sesa@med.ovgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Rare Diseases, Medical Center</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Tüscher, Prof. Dr.</last_name>
      <phone>+49 6131 17 2596</phone>
      <email>tuescher@uni-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Rare Diseases, University Hospital</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Rutsch, Prof. Dr.</last_name>
      <phone>+49 2 51 83 47 700</phone>
      <email>frank.rutsch@ukmuenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Rare Diseases ZSER, University Hospital</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Berneburg, Prof. Dr.</last_name>
      <phone>+49 941 944-9696</phone>
      <email>zser@ukr.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Rare Diseases, University Hospital</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jutta Eymann</last_name>
      <phone>+49 7071 29 85170</phone>
      <email>lotsin@zse-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Rare Diseases, University Hospital</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Hilbig</last_name>
      <phone>+49 731 500-57080</phone>
      <email>zse@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psychosomatic</keyword>
  <keyword>unclear diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rare Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

